文献速递腹部介入US

组织碎化术治疗患者来源胆管癌异种移植小鼠模型

Histotripsy for the Treatment of Cholangiocarcinoma in a Patient-Derived Xenograft Mouse Model.
PubMed 文献 · Ultrasound Med Biol · 2021-11-05

本研究在患者来源胆管癌异种移植小鼠模型中进行慢性实验,使用1 MHz换能器、500脉冲/点的剂量进行组织碎化术。结果显示治疗后26天肿瘤直径平均缩小73%,6只中3只肿瘤在2.5周后不可检测,且治疗组无进展生存期和总生存期显著延长,表明组织碎化术可安全有效治疗胆管癌。

要点

  • 组织碎化术在胆管癌小鼠模型中实现平均73%的肿瘤直径缩小。
  • 治疗需局限于肿瘤内,扩大1-2 mm边缘会显著损伤肠道组织。
  • 治疗后超声可即时显示消融效果,且未观察到显著不良事件。

局限性

  • 研究为小鼠模型,样本量小(n=6),结论外推至临床需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Histotripsy is a focused ultrasound ablation therapy being developed for the treatment of liver tumors. A recent study investigating the feasibility of using histotripsy for the ablation of cholangiocarcinoma (CC), bile duct cancer that is difficult to treat with current therapies because of its location near critical structures and fibrous tissue, reported the feasibility of treating CC in an acute mouse model. Here, we investigate histotripsy for the in vivo ablation of CC in a chronic study using a 1-MHz transducer at an applied dose of 500 pulses/point. A pilot study determined that treating the CC tumors plus a 1- to 2-mm margin induced significant injuries to intestinal tissues, thus precluding the use of this strategy. Next, histotripsy was applied to CCs (n = 6) with the treatment contained to the tumor. Post-treatment, the ablation was visualized using ultrasound, and subjects were monitored over time. Histotripsy achieved an average of 73% reduction of tumor diameter 26 d after treatment, with no significant adverse events. Notably, three of six treated tumors were undetectable after 2.5 wk. The treated animals were found to have significantly increased tumor progression-free and overall survival. Overall, results indicate that histotripsy can be used as a safe and effective method for treating CC.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Hendricks-Wenger, Saunier, Simon, et al. Histotripsy for the Treatment of Cholangiocarcinoma in a Patient-Derived Xenograft Mouse Model. Ultrasound Med Biol. 2021. PMID: 34750030. doi:10.1016/j.ultrasmedbio.2021.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。